

## Grifols invests more than €200 million in fighting Alzheimer's

- *For more than 20 years, the company has focused its investment on diagnostic and treatment solutions to address the complex multifactorial etiology of the disease.*
- *Through the AMBAR® (Alzheimer Management by Albumin Replacement) program, Grifols has demonstrated a 61% slowdown in the progression of the disease in patients with mild to moderate Alzheimer's.*
- *Grifols is currently implementing its program at an AMBAR® center in Barcelona and is in advanced talks with leading Spanish hospital groups to open new centers in Spain. The company is also considering opening new facilities in Germany and the United Kingdom.*

**Barcelona, September 19, 2025.** Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leader in plasma-derived medicines, has invested more than €200 million to-date in the fight against Alzheimer's disease. This investment, made over the last 20 years, is part of the company's efforts in innovation to develop potential new treatments for neurological diseases and other therapeutic areas.

Among its main investments in this field is the innovative AMBAR® (Alzheimer's Management by Albumin Replacement) clinical program, based on the periodic removal of plasma and its replacement with a solution of albumin, a plasma protein. This Grifols clinical program has been shown to slow cognitive and functional decline in patients with mild to moderate Alzheimer's disease. Specifically, the primary efficacy variables evaluated [the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive) and ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living) scales] showed a 61% reduction in disease progression for both measures in the cohort of patients with mild and moderate Alzheimer's disease.

The treatment is based on the hypothesis that much of the beta-amyloid, one of the proteins that accumulates in the brains of people with Alzheimer's, circulates in the plasma, bound to albumin. By removing this plasma, the displacement of beta-amyloid from the brain would be promoted, which would help limit the impact of the disease on the patient's cognitive functions. In addition, patients can also benefit from the antioxidant and anti-inflammatory properties of albumin.

This program, included in the medical guidelines of the renowned ASFA (American Society for Apheresis), has been in place since 2021 at the first AMBAR® center, which the company opened in Barcelona in collaboration with the ACE Foundation. Due to its success, Grifols is currently in advanced talks with leading Spanish hospital groups to open new AMBAR centers in Spain and is also considering opening new facilities in Germany and the United Kingdom.

The project, the result of collaboration between Grifols, the ACE Foundation in Barcelona, and the Alzheimer's Disease Research Center at the University of Pittsburgh, is part of the company's comprehensive Alzheimer's research strategy, which began in 2004 after multiple preclinical trials, pilot studies and a phase II trial. The results have been published in the journal Alzheimer's &

Dementia: The Journal of the Alzheimer's Association and presented at leading international conferences such as CTAD, AD/PD, and AAIC.

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [www.grifols.com](http://www.grifols.com)

## MEDIA CONTACTS:

### Grifols Press Office

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## LEGAL DISCLAIMER

*The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.*